Statements (47)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
recombinant protein
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
lyophilized form
|
| gptkbp:built |
human_factor_IX_gene
|
| gptkbp:canBe |
thromboembolic events
|
| gptkbp:clinicalTrials |
ongoing
|
| gptkbp:contraindication |
known hypersensitivity to components
|
| gptkbp:developedBy |
biotechnology companies
|
| gptkbp:endOfLife |
18 to 24 hours
|
| gptkbp:financial_aid |
stable at room temperature for limited time
|
| gptkbp:hasBrand |
Alprolix
|
| gptkbp:hasWeight |
approximately 50 kDa
|
| https://www.w3.org/2000/01/rdf-schema#label |
recombinant factor IX
|
| gptkbp:involvedIn |
blood coagulation
|
| gptkbp:isAssociatedWith |
improved quality of life
bleeding episodes |
| gptkbp:isAttendedBy |
factor VIII
|
| gptkbp:isAvailableIn |
various dosages
|
| gptkbp:isAvenueFor |
as needed for bleeding
|
| gptkbp:isConsidered |
a safe alternative to plasma-derived products
a_breakthrough_in_hemophilia_treatment |
| gptkbp:isIncorporatedIn |
bioreactors
|
| gptkbp:isNear |
a blood product
a cure for hemophilia B |
| gptkbp:isPartOf |
factor replacement therapy
emergency treatment protocols comprehensive_care_for_hemophilia hemophilia_treatment_regimen |
| gptkbp:isRecognizedFor |
patients with severe hemophilia B
|
| gptkbp:isSubjectTo |
regulatory oversight
|
| gptkbp:issuedBy |
intravenous injection
|
| gptkbp:isUsedFor |
pediatric patients
other clotting factors preventing spontaneous bleeding |
| gptkbp:isUsedIn |
surgery_for_hemophilia_patients
|
| gptkbp:isUtilizedIn |
clinical studies
|
| gptkbp:lastProduced |
1997
|
| gptkbp:mandates |
prophylaxis of bleeding episodes
|
| gptkbp:marketedAs |
Benefix
|
| gptkbp:producedBy |
genetically modified cells
|
| gptkbp:produces |
gptkb:CHO_cells
|
| gptkbp:requires |
patient education
factor IX levels |
| gptkbp:route |
IV infusion
|
| gptkbp:sideEffect |
allergic reactions
|
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
treatment of hemophilia B
|